Literature DB >> 3687163

[Classification and scope of clinical variations of Melkersson-Rosenthal syndrome].

O P Hornstein1, N Stosiek, A Schönberger, M Meisel-Stosiek.   

Abstract

Apart from the apparent trias of oro-facial swellings, facial paresis, and lingua plicata (LP), Melkersson-Rosenthal syndrome (MRS) comprises a variety of complex signs and symptoms. During the last 18 years, 73 patients suffering from MRS were admitted to our hospital. Re-examination of 42 out of these patients and evaluation of all data available proved preceding facial paresis(es) in only 34% of all cases and LP of various degrees in 52%. In more than 80%, however, we found vasomotoric, sialo-secretory, or other neurovegetative "minor signs", locally and/or temporally connected with swellings of either skin or mucosa. Since such minor signs are essential for the diagnosis and the understanding of both "complete" and "incomplete" forms of MRS (either associated with or without typical cheilitis granulomatosa), we worked out a classification of MRS considering the dermal, neurological, and neurovegetative affections observed in our cases and according to the relevant literature. A systematic classification like this, which takes into account the diagnostic signification of the findings, allows exact recognition of "incomplete" forms of MRS and represents a conditio sine qua non with regard to family studies and the follow-up of patients concerned.

Entities:  

Mesh:

Year:  1987        PMID: 3687163

Source DB:  PubMed          Journal:  Z Hautkr        ISSN: 0301-0481


  3 in total

1.  The Melkersson Rosenthal syndrome--a differential diagnosis of facial sarcoidosis.

Authors:  D S McGrath; C Doyle; C P Bredin
Journal:  Ir J Med Sci       Date:  1997 Oct-Dec       Impact factor: 1.568

2.  A 30-year follow-up study of patients with Melkersson-Rosenthal syndrome shows an association to inflammatory bowel disease.

Authors:  Anu Haaramo; Kaija-Leena Kolho; Anne Pitkäranta; Mervi Kanerva
Journal:  Ann Med       Date:  2019-04-13       Impact factor: 4.709

3.  [Unilateral facial edematous granulomatosis. Initial symptom of basalioma].

Authors:  S M Erdmann; C Bangard; A Rübben; P Poblete-Gutiérrez
Journal:  Hautarzt       Date:  2004-01       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.